Anika Therapeutics
ANIK
121 hedge funds and large institutions have $321M invested in Anika Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 47 increasing their positions, 41 reducing their positions, and 15 closing their positions.
358% more call options, than puts
Call options by funds: $1.97M | Put options by funds: $431K
15% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 41
6% more capital invested
Capital invested by funds: $302M → $321M (+$18.4M)
0.87% less ownership
Funds ownership: 93.11% → 92.24% (-0.87%)
3% less funds holding
Funds holding: 125 → 121 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$7.78M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$3.91M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.59M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.18M |
| 5 |
BlackRock
New York
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Capital Management
Glen Allen,
Virginia
|
-$3.98M |
| 2 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
-$2.52M |
| 3 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$2.51M |
| 4 |
KLC
Kent Lake Capital
Reno,
Nevada
|
-$2.2M |
| 5 |
Goldman Sachs
New York
|
-$1.83M |
ANIK Hedge Fund Activity: Q3 2022 in Review
121 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2022, worth a combined $321M — up 6.1% from $302M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ANIK and 11 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 47 added.
The largest buyer was Trigran Investments, adding an estimated $7.78M. The largest seller was Capital Management, cutting an estimated $3.98M.
- 121 institutional investors held Anika Therapeutics (ANIK) as of Q3 2022, down from 125 in Q2 2022.
- Funds reported $321M of Anika Therapeutics stock for Q3 2022, up 6.1% quarter-over-quarter.
- 11 funds opened new Anika Therapeutics positions in Q3 2022 and 15 closed out, a net change of -4 holders.
- The largest Anika Therapeutics buyer in Q3 2022 was Trigran Investments, an estimated $7.78M added.
- The largest Anika Therapeutics seller in Q3 2022 was Capital Management, an estimated $3.98M sold.
Based on aggregated 13F filings for Q3 2022.